SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Lorraine Hansberry — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLorraine Hansberry
Date of birth1930-05-19
IdentifiersMRN HR-ML034-SYN-TD; SSN (made up) 000-34-7158
Document date1963-06-29
AuthorOdette Marchetti-Fields, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review on day 1 of cycle 4 of modified FOLFIRINOX. [S]

History of Present Illness

Ms. Hansberry returns on the first day of her fourth cycle; cycles 1 to 3 were given on schedule. After each cycle she has nausea for a day or two, controlled with olanzapine at night, and two or three loose stools on days 3 to 5, settled with loperamide. For a few days after each cycle cold drinks hurt her throat and her fingers and toes tingle in the cold, and the fingertips now tingle mildly between cycles; she can still type and do buttons. Pain is 2 out of 10 with one or two oxycodone tablets a day, and she sleeps through. She writes three mornings a week. Her stools are formed with pancrelipase and her weight is steady. Home fasting glucose readings are 110 to 130 mg/dL. She has had no bleeding or black stools since the iron. The germline panel and the tumor profile have both resulted. She has had no thoughts of self-harm. [S]

ElementDetail
TreatmentCycles 1 to 3 on schedule; cycle 4 today
EffectsNausea one or two days; loose stools days 3 to 5; cold-induced tingling, now mild between cycles
Genetic resultsGermline panel negative; tumor KRAS G12D, TP53 and CDKN2A alterations, microsatellite stable, no BRCA1, BRCA2 or PALB2 variant, no NTRK, NRG1 or ALK fusion
Pain2 out of 10 on oxycodone once or twice a day
WritingThree mornings a week

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired for three days after each cycle; weight 54.8 kg; no fever
GastrointestinalPositiveNausea one or two days per cycle; loose stools days 3 to 5; no black stools
NeurologicalPositiveCold-induced tingling after each cycle; mild fingertip tingling between cycles; no weakness
Hematologic and lymphaticNegativeNo bleeding or bruising
CardiovascularNegativeNo leg swelling or calf pain
PsychiatricPositiveWorried before each scan and test; PHQ-9 8, GAD-7 9; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfastOne tablet daily before breakfastOral route1963-04-20activeS
Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart750 mg intravenously; two doses one week apartIntravenous route1963-04-24 to 1963-05-01completedS
Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for painOne tablet every 4 hours as neededOral route1963-05-04activeS
Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodoneTwo tablets at nightOral route1963-05-04activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snackTwo capsules with each meal, one with each snackOral route1963-05-04 to 1963-10-05completedS
Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route1963-05-18 to 1963-07-27completedS
Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5Day 1 every 14 days, cycles 1 to 5Intravenous route1963-05-18 to 1963-07-13completedS
Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route1963-05-18 to 1963-07-27completedS
Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus46-hour infusion from day 1 every 14 days for six cyclesIntravenous route1963-05-18 to 1963-07-29completedS
Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected6 mg on day 3 of each cycleSubcutaneous route1963-05-20 to 1963-07-29completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route1963-05-18activeS
Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycleOne tablet at night on days 1 to 4Oral route1963-05-18activeS
Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed4 mg at onset, then 2 mg after each loose stoolOral route1963-05-18activeS
Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgeryOne tablet twice dailyOral route1963-06-29 to 1963-08-21completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1963-06-29Body height163cmS
1963-06-29Body weight54.8kgS
1963-06-29Body mass index (BMI) [Ratio]20.6kg/m2S
1963-06-29Systolic blood pressure110mm[Hg]S
1963-06-29Diastolic blood pressure70mm[Hg]S
1963-06-29Heart rate84/minS
1963-06-29Respiratory rate16/minS
1963-06-29Body temperature36.6CelS
1963-06-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1963-06-29Hemoglobin [Mass/volume] in Blood11.2g/dL12-15.5 g/dLLowS
1963-06-29Leukocytes [#/volume] in Blood by Automated count8.910*3/uL4-11 10*3/uLNormalS
1963-06-29Neutrophils [#/volume] in Blood by Automated count5.810*3/uL1.5-7.7 10*3/uLNormalS
1963-06-29Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
1963-06-29Creatinine [Mass/volume] in Serum or Plasma0.72mg/dL0.59-1.04 mg/dLNormalS
1963-06-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1958)/1.73 sq M114mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1963-06-29Glucose [Mass/volume] in Serum or Plasma128mg/dL70-99 mg/dLHighS
1963-06-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-35 U/LNormalS
1963-06-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-35 U/LNormalS
1963-06-29Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma120U/L35-104 U/LHighS
1963-06-29Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1963-06-29Albumin [Mass/volume] in Serum or Plasma3.5g/dL3.5-5 g/dLNormalS
1963-06-29Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.7-2.2 mg/dLNormalS
1963-06-29Ferritin [Mass/volume] in Serum or Plasma88ng/mL15-150 ng/mLNormalS
1963-06-29Cancer Ag 19-9 [Units/volume] in Serum or Plasma210U/mL<=35 U/mLHighS
1963-06-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
1963-06-29Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]9{score}S
1963-06-29Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S

Physical Exam

Vital signs recorded on 1963-06-29; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 54.8 kg; blood pressure 110/70, pulse 84
EyesNo icterus
AbdomenMild epigastric tenderness; port site clean
NeurologicalLight touch slightly reduced at the fingertips; vibration sense and reflexes normal; fine finger movements normal (grade 1 sensory neuropathy)
ExtremitiesNo leg swelling
PsychiatricEngaged, dry humor, organized

Problems

ProblemClinical statusVerificationCodeProvenance
Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this weekresolvedconfirmed R10.13S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mLactiveconfirmed D50.0S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers.
New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2resolvedconfirmed R73.09S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit.
Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differentlyactiveconfirmed C25.0S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md.
Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dLactiveconfirmed E08.9S — Synthetic consequence of the synthetic tumor.
Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight lossactiveconfirmed K86.81S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer.
Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by itactiveconfirmed G89.3S — Synthetic symptom of the synthetic tumor.
Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCPactiveconfirmed K83.1S — Synthetic consequence of the synthetic tumor.
Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttonsactiveconfirmed G62.0S — Synthetic common effect of oxaliplatin.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with neutrophils and plateletsBefore each chemotherapy cycle and at each visitCompleted todayHemoglobin 11.2 g/dL, white cells 8.9, neutrophils 5.8, platelets 214; full dose
LaboratoryKidney and liver function, albuminBefore each cycleCompleted todayCreatinine 0.72 mg/dL, eGFR 114; ALT 26, AST 27, alkaline phosphatase 120 U/L, bilirubin 0.6 mg/dL; albumin 3.5 g/dL
LaboratoryMagnesiumBefore each cycleCompleted today1.9 mg/dL
LaboratoryFerritin after intravenous ironFour to eight weeks after the last doseCompleted today88 ng/mL
LaboratoryCA 19-9At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six monthsCompleted today210 U/mL, from 486 at diagnosis
ImagingInterim restaging CTEvery two months during chemotherapy before surgeryOrderedOrdered today for two weeks from now, before cycle 5
LaboratoryGermline multigene panelOnce, at diagnosisUp to dateNegative for pathogenic variants; reviewed with the genetic counselor; no cascade testing needed
LaboratoryTumor molecular profilingAt diagnosisUp to dateKRAS G12D, TP53 and CDKN2A alterations; microsatellite stable; no BRCA1, BRCA2 or PALB2 variant; no NTRK, NRG1 or ALK fusion
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore chemotherapyUp to dateNegative before cycle 1; hepatitis B surface antibody negative, so vaccination after chemotherapy
ExaminationOxaliplatin neuropathy: symptoms and examinationBefore each oxaliplatin doseCompleted todayGrade 1 sensory neuropathy; full dose continues
Medication safetyNausea, vomiting and diarrhea controlEach cycleCompleted todayNausea one or two days on olanzapine; loose stools controlled with loperamide
Medication safetyVenous thromboembolism prophylaxisDuring chemotherapyCompleted todayNo bleeding for eight weeks and hemoglobin 11.2 g/dL: apixaban 2.5 mg twice daily started today, with teaching on bleeding signs
SurveyPain score and opioid reviewEach visitCompleted todayPain 2 out of 10
Self-managementWeight, nutrition and enzyme replacementEach visitCompleted todayWeight 54.8 kg, 1 percent below the weight at diagnosis; stools formed on pancrelipase
LaboratoryGlucose and home readingsEach visit and before each cycleCompleted todayGlucose 128 mg/dL; home fasting 110 to 130
ExaminationDilated eye examination and urine albumin-to-creatinine ratioAt diagnosis of diabetes, then yearlyDeferredA deviation: the dilated eye examination and urine albumin-to-creatinine ratio planned when diabetes was diagnosed were not arranged, amid staging and the start of chemotherapy. Harm is unlikely after two months of mild diabetes, but the check is a standard of care. Corrective action: both booked with the visit after surgery, when treatment visits are fewer
SurveyDistress and depression screen (PHQ-9, GAD-7)At diagnosis, at each treatment phase, and when symptoms changeCompleted todayPHQ-9 8 and GAD-7 9; worry before scans; she sees the palliative care social worker monthly

Goal progress:

Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Stoffel EM, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2019;37(2):153-164 (PMID 30457921) (2019); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (PMID 32658626) (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (PMID 32663120) (2020); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Interim CT in two weeks. Cycles 5 and 6 every two weeks. Restaging CT and review after cycle 6. Call at once for fever of 38.0 °C or more, diarrhea not controlled by loperamide, bleeding, or yellow eyes. Next scheduled visit 1963-08-10: after six cycles: restaging CT and CA 19-9, decision for surgery, and preparation for pancreaticoduodenectomy. [S]